4-(3-fluoropropyl)glutamic acid: Clinical Trials

10 trials of 4-(3-fluoropropyl)glutamic acid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated, 1 recruiting, 1 withdrawn. 7 Phase 2, 2 Early Phase 1, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Recruiting 1, Terminated 1
Early Phase 12Terminated 1, Withdrawn 1
Phase 12Recruiting 1, Terminated 1

Follow 4-(3-fluoropropyl)glutamic acid: new trials by email Literature Review of 4-(3-fluoropropyl)glutamic acid trials Research Report on 4-(3-fluoropropyl)glutamic acid

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1 / Phase 2RecruitingVanderbilt-Ingram Cancer Center252023-05-092024-10-17
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
18F-FSPG, 11C-Glutamine - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Early Phase 1TerminatedM.D. Anderson Cancer Center32022-09-142025-04-09
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
[18F]FSPG - Graft Rejection, Heart Transplantation
Phase 2CompletedAsan Medical Center72020-11-182023-07-20
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392 - Cigarette Smoker, Current Smoker
Phase 2CompletedAndrei Iagaru152019-02-042025-04-09
Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease
[18F]FSPG - Inflammatory Bowel Diseases, Ulcerative Colitis
Phase 2CompletedAsan Foundation202018-08-142020-12-14
PET Imaging of Ovarian Carcinoma With 18F-FSPG
(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG), Positron Emission Tomography, Laboratory Biomarker Analysis - Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer
Early Phase 1WithdrawnVanderbilt-Ingram Cancer Center2018-06-012018-06-06
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
18F-FSPG - Cardiac Sarcoidosis, Myocardial Inflammation
Phase 2TerminatedStanford University452017-08-022023-04-07
18F-FSPG PET/CT for Cancer Patients on Therapy
18F-FSPG, 18F-FDG - B-Cell Neoplasm, Estrogen Receptor Negative
Phase 2CompletedAndrei Iagaru72015-07-012019-01-03
18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
Computed Tomography, fluorodeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392 - Lung Carcinoma, Solitary Pulmonary Nodule
Phase 2CompletedVanderbilt-Ingram Cancer Center462015-06-162022-10-19
PET Imaging of Intracranial Cancers With 18F-FSPG
18F-FSPG - Brain Cancer
Phase 1TerminatedLantheus Biosciences Ltd.262014-11-012016-09-02

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Lung Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Renal Cell (1)  ·  Cigarette Smoking (1)  ·  Colitis, Ulcerative (1)  ·  Crohn Disease (1)  ·  Fallopian Tube Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Inflammatory Bowel Diseases (1)  ·  Lymphoma, B-Cell (1)  ·  Mesothelioma (1)  ·  Multiple Pulmonary Nodules (1)  ·  Myocarditis (1)

Sponsors

Vanderbilt-Ingram Cancer Center (3)  ·  Andrei Iagaru (2)  ·  Asan Foundation (1)  ·  Asan Medical Center (1)  ·  Lantheus Biosciences Ltd. (1)  ·  M.D. Anderson Cancer Center (1)  ·  Stanford University (1)

Countries

United States (7)  ·  South Korea (2)

Top investigators

Andrei Iagaru, MD (1)  ·  Andrei M Iagaru, MD (1)  ·  Carina Mari Aparici (1)  ·  Chirayu Shah, MD (1)  ·  Dae Hyuk Moon, MD (1)  ·  Evan Osmundson, MD, PhD (1)  ·  Lesley Flynt, MD (1)  ·  Marta Crispens, MD (1)  ·  Norman Koglin, PhD (1)

Results publications

PMID 35191738

NIH funding

P30CA068485 (2), P30CA124435 (1)